An experimental in-vitro study to evaluate the anti-helicobacter activity of Glycyrrhetinic acid

Open access


Aim: The aim of this study was to investigate the in-vitro efficacy of Glycyrrhetinic acid against Helicobacter pylori (H. pylori) strains, as compared with conventional antibacterial agents.

Methods: A total of 41 H. pylori isolates were used, 6 of which were of standard strains (NCTC 1637), 8 of which were drug-sensitive, and 27 were resistant to drugs isolates. Clarithromycin and metronidazole resistance in all strains of H. pylori were determined by the Epsilometer test (E-test) method. MIC study was performed by using microdilution broth method.

Results: Glycyrrhetinic acid was found to be effective against H. pylori NCTC 1637 in doses of 12.0±4.38 µg/mL, while the MIC value of clinical H. pylori isolates susceptible to antimicrobials was 20.8±10.11 µg/ml. It was found that the MIC values for antimicrobial-sensitive clinical H. pylori isolates was higher when compared with H. pylori NCTC 1637 strains. The MIC values of the standard antimicrobial agents against drug-resistant H. pylori strains were higher than H. pylori NCTC 1637 strains and drug-sensitive H. pylori strains. The MIC value was found to be 14.22±7.77 µg/ml for metronidazole, 3.89±1.90 µg/ml for clarithromycin, 2.33±1.0 µg/ml for amoxicillin, 2.44±0.88 µg/ml for levofloxacin and 4.89±2.47 µg/ml for tetracycline, whereas the MIC value of Glycyrrhetinic acid was 26.67±8.0 µg/ml in metronidazole-resistant H. pylori isolates. Besides, MIC values of the antimicrobials and 18ß-Glycyrrhetinic acid among the strains resistant to clarithromycin were as follows: 3.25±2.12 µg/ml for metronidazole, 9.71±4.54 µg/ml for clarithromycin, 2.06±1.32 µg/ml for amoxicillin, 3.88±4.22 µg/ml for levofloaxacin and 3.25±1.04 µg/mL for tetracycline and 22.0±11.11 µg/ml for Glycyrrhetinic acid.

Conclusion: Glycyrrhetinic acid had significant antimicrobial activity against H. pylori strains. Although further in-vivo studies are needed on antimicrobial activity of Glycyrrhetinic acid, increased resistance to drugs currently used in treatment suggests that Glycyrrhetinic acid may be a potential agent for the treatment of H. pylori.

1. Tonkic A, Tonkic M, Lehours P, Megraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 2012; 17:1-8. DOI: 10.1111/j.1523-5378.2012.00975.x

2. Silva O, Viegas S, de Mello-Sampayo C, Costa MJ, Serrano R, Cabrita J, Gomes ET. Anti-Helicobacter pylori activity of terminalia macroptera root. Fitoterapia 2012; 83(5):872-6. DOI: 10.1016/j.fitote.2012.03.019

3. Choi JH, Yang YJ, Bang CS, Lee JJ, Baik GH. Current Status of the third-line Helicobacter pylori eradication. Gastroenterol Res Pract. 2018; 2018:6523653. DOI: 10.1155/2018/6523653

4. Chen L, He J, Wang L, Ge Q, Chu H, Chen Y, et al. Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China:an open-label, randomized clinical trial. Clin Exp Med. 2018 Jun 6. doi:10.1007/s10238-018-0510-9. [Epub ahead of print] DOI: 10.1007/s10238-018-0510-9

5. Wu TS, Hu HM, Kuo FC, Kuo CH. Kaohsiung J. Eradication of Helicobacter pylori infection. Med Sci. 2014; 30(4):167-72. DOI: 10.1016/j.kjms.2013.11.003

6. Hu Y, Zhu Y, Lu NH. Novel and Effective Therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance. Front Cell Infect Microbiol. 2017; 7:168. DOI: 10.3389/fcimb.2017.00168

7. O’Connor A, Gisbert JP, McNamara D, O’Morain C. Treatment of Helicobacter pylori infection 2010. Helicobacter. 2010; Suppl 1:46-52. DOI: 10.1111/j.1523-5378.2010.00774.x

8. Talebi Bezmin Abadi A, Yamaoka Y. Helicobacter pylori therapy and clinical perspective. J Glob Antimicrob Resist. 2018; pii:S2213-7165(18)30057-2.

9. Amin M, Anwar F, Naz F, Mehmood T, Saari N. Anti-Helicobacter pylori and urease inhibition activities of some traditional medicinal plants. Molecules. 2013; 18(2):2135-49. DOI: 10.3390/molecules18022135

10. Safavi M, Shams-Ardakani M, Foroumadi A. Medicinal plants in the treatment of Helicobacter pylori infections. Pharm Biol. 2015; 53(7):939-60. DOI: 10.3109/13880209.2014.952837

11. Li K, Ji S, Song W, Kuang Y, Lin Y, Tang S, et al. Glycybridins A-K, bioactive Phenolic compounds from Glycyrrhiza glabra. J Nat Prod. 2017; 80(2):334-46. DOI: 10.1021/acs.jnatprod.6b00783

12. Liu W, Sun Z, Qu J, Yang C, Zhang X, Wei X. Correlation between root respiration and the levels of bio-mass and glycyrrhizic acid in Glycyrrhiza uralensis. Exp Ther Med. 2017; 14(3):2323-8. DOI: 10.3892/etm.2017.4723

13. Kuang Y, Lin Y, Li K, Song W, Ji S, Qiao X, et al. Screening of hepatoprotective compounds from licorice against carbon tetrachloride and acetaminophen induced HepG2 cells injury. Phytomedicine. 2017; 34:59-66. DOI: 10.1016/j.phymed.2017.08.005

14. Mahmoud AM, Hussein OE, Hozayen WG, Abd El-Twab SM. Methotrexate hepatotoxicity is associated with oxidative stress, and down-regulation of PPARγ and Nrf2:Protective effect of 18β-Glycyrrhetinic acid. Chem Biol Interact. 2017; 270:59-72. DOI: 10.1016/j.cbi.2017.04.009

15. Yoshida T, Abe K, Ikeda T, Matsushita T, Wake K, Sato T, et al. Inhibitory effect of glycyrrhizin on lipopolysaccharide and d-galactosamine-induced mouse liver injury. Eur J Pharmacol. 2007; 576(1-3):136-42. DOI: 10.1016/j.ejphar.2007.08.012

16. Fujii S, Morinaga O, Uto T, Nomura S, Shoyama Y. Development of double eastern blotting for major licorice components, glycyrrhizin and liquiritin for chemical quality control of licorice using anti-glycyrrhizin and anti-liquiritin monoclonal antibodies. J Agric Food Chem. 2016; 64(5):1087-93. DOI: 10.1021/acs.jafc.5b04732

17. Fukazawa K, Seki M, Satoh K, Sugano K. Antimicrobial resistance testing of H. pylori epsilometer test and disk diffusion test. Nihon Rinsho. 1999; 57(1):76-80.

18. Owen RJ. Baillieres Clin Gastroenterol. Bacteriology of Helicobacter pylori. 1995; 9(3):415-46.

19. Marginean OC, Stolnicu S. New diagnostic perspectives related to Helicobacter pylori infection in children. Rev Romana Med Lab, 2009; 15(2):61-8.

20. Hirschl AM, Makristathis A. Methods to detect Helicobacter pylori:from culture to molecular biology. Helicobacter. 2007; Suppl 2:6-11. DOI: 10.1111/j.1523-5378.2007.00560.x

21. O’Mahony R, Al-Khtheeri H, Weerasekera D, Fernando N, Vaira D, Holton J, et al. Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori. World Journal of Gastroenterology 2005; 11:7499-507. DOI: 10.3748/wjg.v11.i47.7499

22. Siddique O, Ovalle A, Siddique AS, Moss SF. Helicobacter pylori Infection:An update for the internist in the age of increasing global antibiotic resistance. Am J Med. 2018; 131(5):473-9. DOI: 10.1016/j.amjmed.2017.12.024

23. Johnson KS, Ottemann KM. Colonization, localization, and inflammation:the roles of H. pylori chemotaxis in-vivo. Curr Opin Microbiol. 2018; 41:51-7. DOI: 10.1016/j.mib.2017.11.019

24. Ford AC, Gurusamy KS, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev. 2016; 4:CD003840. DOI: 10.1002/14651858.CD003840.pub5

25. Zhu Y, Zhou X, Wu J, Su J, Zhang G. Risk factors and prevalence of Helicobacter pylori infection in persistent high incidence area of gastric carcinoma in yangzhong city. Gastroenterol Res Pract. 2014; 2014:481365. DOI: 10.1155/2014/481365

26. Pereira MI, Medeiros JA. Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas. World J Gastroenterol. 2014; 20(3):684-98. DOI: 10.3748/wjg.v20.i3.684

27. Bornschein J, Malfertheiner P. Helicobacter pylori and gastric cancer. Dig Dis. 2014; 32(3):249-64. DOI: 10.1159/000357858

28. Watari J, Chen N, Amenta PS, Fukui H, Oshima T, Tomita T, et al. Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World J Gastroenterol. 2014; 20(18):5461-73. DOI: 10.3748/wjg.v20.i18.5461

29. Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 2014; 345(2):196-202. DOI: 10.1016/j.canlet.2013.08.016

30. Nazari S, Rameshrad M, Hosseinzadeh H. Toxicological effects of Glycyrrhiza glabra (Licorice):A Review. Phytother Res. 2017; 31(11):1635-50. DOI: 10.1002/ptr.5893

31. Hosseinzadeh H, Nassiri-Asl M. Pharmacological Effects of Glycyrrhiza spp. and Its Bioactive Constituents:Update and Review. Phytother Res. 2015; 29(12):1868-86. DOI: 10.1002/ptr.5487

32. Wei M, Ma Y, Liu Y, Zhou Y, Men L, Yue K, et al. Urinary metabolomics study on the anti-inflammation effects of flavonoids obtained from glycyrrhiza. J Chromatogr B Analyt Technol Biomed Life Sci. 2018; 1086:1-10. DOI: 10.1016/j.jchromb.2018.04.007

33. Yang N, Patil S, Zhuge J, Wen MC, Bolleddula J, Doddaga S, et al. Glycyrrhiza uralensis flavonoids present in anti-asthma formula, ASHMI™, inhibit memory Th2 responses in vitro and in vivo. Phytother Res. 2013; 27(9):1381-91. DOI: 10.1002/ptr.4862

34. Saeedi M, Morteza-Semnani K, Ghoreishi MR. The treatment of atopic dermatitis with licorice gel. J Dermatolog Treat. 2003; 14(3):153-7. DOI: 10.1080/09546630310014369

35. Fukuchi K, Okudaira N, Adachi K, Odai-Ide R, Watanabe S, Ohno H, et al. Antiviral and antitumor activity of licorice root extracts. In-Vivo. 2016; 30(6):777-85. DOI: 10.21873/invivo.10994

36. Pu JY, He L, Wu SY, Zhang P, Huang X. Anti-virus research of triterpenoids in licorice]. Bing Du Xue Bao. 2013; 29(6):673-9.

37. Fiore C, Eisenhut M, Krausse R, Ragazzi E, Pellati D, Armanini D, et al. Antiviral effects of glycyrrhiza species. Phytother Res. 2008; 22(2):141-8. DOI: 10.1002/ptr.2295

38. Sabouri Ghannad M, Mohammadi A, Safiallahy S, Faradmal J, Azizi M, Ahmadvand Z. The effect of aqueous extract of glycyrrhiza glabra on Herpes simplex virus 1. Jundishapur J Microbiol. 2014; 7(7):e11616. DOI: 10.5812/jjm.11616

39. Kalaigandhi V, Poovendran P, Poogunran E. Antimicrobial activity of glycyrrhiza glabra (licorice) against peptic ulcer produced Helicobacter pylori. Int J Curr Pharm Res. 2011; 3(4):93-5.

40. Raveendra KR, Jayachandra, Srinivasa V, Sushma KR, Allan JJ, Goudar KS, Shivaprasad HN, et al. An extract of Glycyrrhiza glabra (gutgard) alleviates symptoms of functional dyspepsia:a randomized, double-blind, placebo-controlled study. Evid Based Complement Alternat Med. 2012; 2012:216970. DOI: 10.1155/2012/216970

41. Memariani Z, Hajimahmoodi M, Minaee B, Khodagholi F, Yans A, Rahimi R, et al. Protective effect of polyherbal traditional formula consisting of Rosa damascena mill, Glycyrrhiza glabra L. and Nardostachys jatamansi DC., against ethanol-induced gastric ulcer. Iran J Pharm Res. 2017; 16(2):694-707.

42. Asha MK, Debraj D, Prashanth D, Edwin JR, Srikanth HS, Muruganantham N, et al. In vitro anti-Helicobacter pylori activity of a flavonoid rich extract of Glycyrrhiza glabra and its probable mechanisms of action. J Ethnopharmacol. 2013; 145(2):581-6. DOI: 10.1016/j.jep.2012.11.033

43. Wang Y, Wang S, Bao Y, Li T, Chang X, Yang G, et al. Multipathway Integrated adjustment mechanism of glycyrrhiza triterpenes curing gastric ulcer in rats. Pharmacogn Mag. 2017; 13(50):209-215. DOI: 10.4103/0973-1296.204550

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information

IMPACT FACTOR 2018: 0,800
5-year IMPACT FACTOR: 0,655

CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2018: 0.194
Source Normalized Impact per Paper (SNIP) 2018: 0.306


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 172 172 31
PDF Downloads 121 121 12